FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W54408736> ?p ?o ?g. }

• W54408736 endingPage "24" @default.
• W54408736 startingPage "418" @default.
• W54408736 abstract "Osteoporosis is emerging as a leading cause of substantial morbidity in India, particularly in postmenopausal women. Teriparatide (recombinant human parathyroid hormone [1-34]) increases bone formation and improves bone microarchitecture, thereby reducing the risk of fractures. This study was conducted to evaluate the efficacy of teriparatide in increasing bone mineral density (BMD) in postmenopausal women with osteoporosis.A randomised, prospective, multicentre, open-label, controlled study was conducted on 82 postmenopausal women with established osteoporosis. Patients were randomly divided into control and teriparatide groups, each group consisting of 41 patients. All the patients were supplemented with 1000 mg of elemental calcium and 500 IU of vitamin D throughout the study period of 180 days. Besides, teriparatide group patients were administered teriparatide 20 microg daily subcutaneously. Lumbar spine, femoral neck and total hip BMD, bone mineral content (BMC) and bone area were measured by dual energy x-ray absorptiometry (DXA) at baseline and at the end of 6 months of treatment. Bone biomarkers, such as serum bone specific alkaline phosphatase (BSAP) and serum osteocalcin (OC), representing bone formation, and urinary deoxypyridinoline (DPD), representing bone resorption were assessed at baseline, and at 3 and 6 months of treatment.During the study period, 9 patients (11%) were lost to follow-up--6 in control group (7.3%) and 3 in teriparatide group (3.7%). There was an excellent compliance to both oral and injectable medication. The investigational product teriparatide was well tolerated and there were no serious adverse events. In addition, there were no significant differences between the groups in the incidence of adverse events. The percentage of increase in lumbar spine BMD, which is the primary endpoint, was significantly (P < 0.001) higher in teriparatide group compared to that in control group (6.58% vs. 1.06%). Further, teriparatide significantly increased percentage of change in lumbar spine T-score (P < 0.001), BMC (P < 0.001) and bone area (P < 0.028) compared to control group at 6 months. Administration of teriparatide resulted in a significant percentage of increase in all the bone biomarkers in teriparatide group compared to control group patients at 3 and 6 months over baseline, thereby showing that there was a significant increase in bone turnover in teriparatide group of patients.These results show that teriparatide is an effective and safe drug in increasing the BMD and therefore, teriparatide provides yet another new therapeutic option for reducing the risk management of osteoporosis in postmenopausal women (clinicaltrials.gov number, NCT00500409)." @default.
• W54408736 created "2016-06-24" @default.
• W54408736 creator A5019529313 @default.
• W54408736 creator A5034173087 @default.
• W54408736 creator A5038729212 @default.
• W54408736 creator A5043335161 @default.
• W54408736 creator A5043986676 @default.
• W54408736 creator A5044351769 @default.
• W54408736 date "2008-06-01" @default.
• W54408736 modified "2023-09-27" @default.
• W54408736 title "Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience." @default.
• W54408736 cites W179486415 @default.
• W54408736 cites W1991404229 @default.
• W54408736 cites W2005298224 @default.
• W54408736 cites W2015350578 @default.
• W54408736 cites W2042007405 @default.
• W54408736 cites W2076064293 @default.
• W54408736 cites W2085200136 @default.
• W54408736 cites W2089732052 @default.
• W54408736 cites W2109617636 @default.
• W54408736 cites W2112629831 @default.
• W54408736 cites W2127733654 @default.
• W54408736 cites W2156278844 @default.
• W54408736 cites W2314110838 @default.
• W54408736 cites W28497082 @default.
• W54408736 cites W3147453972 @default.
• W54408736 cites W67988562 @default.
• W54408736 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18822620" @default.
• W54408736 hasPublicationYear "2008" @default.
• W54408736 type Work @default.
• W54408736 sameAs 54408736 @default.
• W54408736 citedByCount "10" @default.
• W54408736 countsByYear W544087362012 @default.
• W54408736 countsByYear W544087362014 @default.
• W54408736 countsByYear W544087362015 @default.
• W54408736 countsByYear W544087362018 @default.
• W54408736 countsByYear W544087362019 @default.
• W54408736 countsByYear W544087362020 @default.
• W54408736 crossrefType "journal-article" @default.
• W54408736 hasAuthorship W54408736A5019529313 @default.
• W54408736 hasAuthorship W54408736A5034173087 @default.
• W54408736 hasAuthorship W54408736A5038729212 @default.
• W54408736 hasAuthorship W54408736A5043335161 @default.
• W54408736 hasAuthorship W54408736A5043986676 @default.
• W54408736 hasAuthorship W54408736A5044351769 @default.
• W54408736 hasConcept C126322002 @default.
• W54408736 hasConcept C126894567 @default.
• W54408736 hasConcept C131075544 @default.
• W54408736 hasConcept C141071460 @default.
• W54408736 hasConcept C160160445 @default.
• W54408736 hasConcept C170033053 @default.
• W54408736 hasConcept C181199279 @default.
• W54408736 hasConcept C185592680 @default.
• W54408736 hasConcept C2775854910 @default.
• W54408736 hasConcept C2776541429 @default.
• W54408736 hasConcept C2776886416 @default.
• W54408736 hasConcept C2777308945 @default.
• W54408736 hasConcept C2780787237 @default.
• W54408736 hasConcept C55493867 @default.
• W54408736 hasConcept C673006 @default.
• W54408736 hasConcept C71924100 @default.
• W54408736 hasConceptScore W54408736C126322002 @default.
• W54408736 hasConceptScore W54408736C126894567 @default.
• W54408736 hasConceptScore W54408736C131075544 @default.
• W54408736 hasConceptScore W54408736C141071460 @default.
• W54408736 hasConceptScore W54408736C160160445 @default.
• W54408736 hasConceptScore W54408736C170033053 @default.
• W54408736 hasConceptScore W54408736C181199279 @default.
• W54408736 hasConceptScore W54408736C185592680 @default.
• W54408736 hasConceptScore W54408736C2775854910 @default.
• W54408736 hasConceptScore W54408736C2776541429 @default.
• W54408736 hasConceptScore W54408736C2776886416 @default.
• W54408736 hasConceptScore W54408736C2777308945 @default.
• W54408736 hasConceptScore W54408736C2780787237 @default.
• W54408736 hasConceptScore W54408736C55493867 @default.
• W54408736 hasConceptScore W54408736C673006 @default.
• W54408736 hasConceptScore W54408736C71924100 @default.
• W54408736 hasLocation W544087361 @default.
• W54408736 hasOpenAccess W54408736 @default.
• W54408736 hasPrimaryLocation W544087361 @default.
• W54408736 hasRelatedWork W1551963378 @default.
• W54408736 hasRelatedWork W1980060473 @default.
• W54408736 hasRelatedWork W2005373764 @default.
• W54408736 hasRelatedWork W2019881154 @default.
• W54408736 hasRelatedWork W2021052117 @default.
• W54408736 hasRelatedWork W2037210676 @default.
• W54408736 hasRelatedWork W2137880068 @default.
• W54408736 hasRelatedWork W2335178464 @default.
• W54408736 hasRelatedWork W2350989811 @default.
• W54408736 hasRelatedWork W2379053629 @default.
• W54408736 hasRelatedWork W2393584914 @default.
• W54408736 hasRelatedWork W2625206043 @default.
• W54408736 hasRelatedWork W2738136796 @default.
• W54408736 hasRelatedWork W2761887483 @default.
• W54408736 hasRelatedWork W2896232898 @default.
• W54408736 hasRelatedWork W2904566125 @default.
• W54408736 hasRelatedWork W2950518715 @default.
• W54408736 hasRelatedWork W2983293648 @default.

• next